European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
1. Tezspire received a positive EU approval recommendation for CRSwNP. 2. WAYPOINT trial showed significant reduction in nasal polyp severity. 3. Tezspire eliminated surgery needs and reduced corticosteroid treatments. 4. Koselugo also recommended for neurofibromatosis type 1, enhancing AZN's portfolio. 5. AZN shares increased 1.78%, reflecting investor optimism.